Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from AxoGen ( (AXGN) ).
On April 28, 2026, Axogen reported first-quarter 2026 revenue of $61.5 million, a 26.6% increase over the prior-year period, with gross margin improving to 75.2%. Despite a GAAP net loss of $19.6 million, the company posted adjusted net income of $4.1 million and adjusted EBITDA of $5.7 million, supported by broad-based double-digit growth across all target markets and a strengthened cash position of $103.6 million.
The company highlighted favorable reimbursement and coverage developments, including a new CMS Level 3 nerve procedure code effective January 1, 2026 and positive decisions from major commercial insurers, which enhance economics for its Avance product. In January 2026, Axogen completed an upsized equity offering, using part of the $133.3 million in net proceeds to fully repay its Oberland loan facility and retaining remaining funds for general corporate purposes, and it raised full-year 2026 revenue guidance to at least 20% growth, or $270 million, while targeting positive free cash flow for the year.
The most recent analyst rating on (AXGN) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.
Spark’s Take on AXGN Stock
According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.
The score is driven primarily by improving fundamentals (strong revenue growth, high gross margins, and sharply reduced debt) but is held back by ongoing GAAP losses and negative TTM free cash flow. The latest earnings call was constructive with ≥18% growth guidance and an expectation of full-year 2026 free-cash-flow positivity, while technicals are mixed with a softer near-term trend.
To see Spark’s full report on AXGN stock, click here.
More about AxoGen
Axogen, Inc., listed on Nasdaq as AXGN, is a medical technology company focused on peripheral nerve regeneration and repair. The company develops and commercializes surgical solutions such as Avance nerve grafts and Axoguard connectors and protectors, targeting procedures in extremities, oral and maxillofacial, head and neck, and breast surgery markets.
Average Trading Volume: 1,022,344
Technical Sentiment Signal: Buy
Current Market Cap: $2.04B
For an in-depth examination of AXGN stock, go to TipRanks’ Overview page.